Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Bayer markets GW Pharmaceuticals' cannabis drug; terminated

Executive Summary

In its first commercial collaboration, GW Pharmaceuticals PLC, a company developing drugs derived from cannabis, licensed Bayer exclusive UK marketing rights to its sublingual cannabis extract spray. The candidate, in regulatory review to treat neuropathic pain and symptoms of multiple sclerosis, will be sold by prescription in the UK under the brandname Sativex.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Marketing (Licensing)

Related Companies